Thameco Pharmaceutical has begun domestic manufacturing of azithromycin as part of Syria’s fight against the COVID pandemic. Dr. Fida Ali, the company’s General Manager, made this exciting announcement in an interview with SANA.
Dr. Ali noted that Thameco has also been authorized by the government to increase production cetamol (acetaminophen), vitamin C, and other essential medications, supplements, and hand sanitizer in quantities required to meet the needs of the population.
Long time readers of Syria News may recognize the name, Thameco Pharmaceutical. It is the largest in Syria and in 2013, the NATO supported FSA terrorists bombed its warehouses in Eastern Ghouta, “to increase the suffering level on the Syrian people.”
Azithromycin is a macrolide that has been successfully used in the treatment of COVID. While it is well known by the layperson that antibiotics cannot cure viruses, the layperson has not been taught that viral and bacterial pathogens engage in cooperation to produce respiratory disease. Obliteration of the pathogenic bacterium helps to weaken the virus.
Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article.